Tenax Therapeutics (TENX) Prices Prices 8 67M Share Offering at $1 80/sh streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
01.02.2023 - Patent is expected to provide additional intellectual property protection until 2040 Prevalence estimates indicate that PH-HFpEF affects over 1,500,000 patients in the U.S. There are currently no FDA approved treatments for PH-HFpEF CHAPEL HILL, . Seite 1
Tenax Therapeutics (TENX) Granted Notice of Allowance for U S Patent Application Covering Use of IV Levosimendan in PH-HFpEF streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Patent is expected to provide additional intellectual property protection until 2040 Prevalence estimates indicate that PH-HFpEF affects over 1,500,000.
Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF) - read this article along with other careers information, tips and advice on BioSpace